{
    "clinical_study": {
        "@rank": "104330", 
        "acronym": "PG101", 
        "arm_group": [
            {
                "arm_group_label": "PG101 0.25%", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical application of drug"
            }, 
            {
                "arm_group_label": "PG101 1.0%", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical application of drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Topical application of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of 0.25% PG101 and 1.0% PG101 topical gel suspension\n      compared to placebo when administered two times daily for 14 days in subjects diagnosed with\n      dry eye syndrome"
        }, 
        "brief_title": "Safety and Efficacy of PG101 for Dry Eye Syndrome", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "detailed_description": {
            "textblock": "The topical product PG101 is expected to be efficacious in treating the symptoms of dry eye\n      such as discomfort, dryness, grittiness, burning, stinging, photophobia, lid friction, mucus\n      discharge and hyper-tearing.  Two concentrations (0.25% and 1.0%) are included in the study\n      to determine if there is a dose response effect."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be male or female of any race, at least 18 years of age\n\n          -  Have provided verbal and written informed consent\n\n          -  Be able and willing to follow instructions, including participation in all study\n             assessments and visits\n\n          -  Have a reported history of dry eye syndrome\n\n          -  Have a history of use or desire to use eye drops for dry eye\n\n          -  If a woman of childbearing potential, have a negative pregnancy test at Visit 1 and\n             be using an adequate method of birth control throughout the study period\n\n          -  Have a best corrected visual acuity of +0.70 logMAR or better in both eyes\n\n        Exclusion Criteria:\n\n          -  Have any clinically significant eye findings that require therapeutic treatment or\n             may interfere with study parameters\n\n          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or\n             active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1\n\n          -  Be a woman who is pregnant, nursing or planning a pregnancy\n\n          -  Have a known allergy and/or sensitivity to the test article or its components\n\n          -  Have a condition or be in a situation which the investigator feels may put the\n             subject at significant risk, may confound the study results, or may interfere\n             significantly with the subject's participation in the study\n\n          -  Be currently enrolled in an investigational drug or device study or have used an\n             investigational drug or device within 30 days of Visit 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078661", 
            "org_study_id": "RP-PG-EF001", 
            "secondary_id": "13-110-0002"
        }, 
        "intervention": {
            "arm_group_label": [
                "PG101 0.25%", 
                "PG101 1.0%", 
                "Placebo"
            ], 
            "description": "A topical gel containing either 1% or 0.25% PG101 active.", 
            "intervention_name": "PG101", 
            "intervention_type": "Drug", 
            "other_name": [
                "Topical gel", 
                "Topical gel suspension"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Keratoconjunctivitis sicca", 
            "Dry eye"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Andover Eye"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome", 
        "overall_official": {
            "affiliation": "Andover Eye", 
            "last_name": "Gail Torkildsen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Dry eye ocular symptoms measured are:  Ocular discomfort, dryness, grittiness, burning, stinging, photophobia, lid friction, mucus discharge and hyper-tearing.", 
            "measure": "At least one dry eye ocular symptom", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078661"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Dry eye ocular signs measured are:  Corneal and conjunctival staining, tear break up time, OPI 2.0, Schirmer tear test, quality of life, and conjunctival redness", 
            "measure": "At least one dry eye ocular sign measure.", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 weeks"
        }, 
        "source": "Rhodes Pharmaceuticals, L.P.", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Rhodes Pharmaceuticals, L.P.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}